Ductal adenocarcinoma of the pancreas: Expression of growth factor receptors, oncogenes and suppressor genes, and their relationship to pathological features, staging and survival

Lozano-Leon,Antonio; Perez-Quintela,Begona   Vieites; Iglesias-García,Julio; Lariño-Noia,Jose; Varo,Evaristo; Forteza,Jeronimo; Domínguez-Muñoz,J.   Enrique

doi:10.3892/ol.2010.206

Ductal adenocarcinoma of the pancreas: Expression of growth factor receptors, oncogenes and suppressor genes, and their relationship to pathological features, staging and survival

Authors:
- Antonio Lozano-Leon
- Begona Vieites Perez-Quintela
- Julio Iglesias-García
- Jose Lariño-Noia
- Evaristo Varo
- Jeronimo Forteza
- J. Enrique Domínguez-Muñoz
View Affiliations

Affiliations: Department of Gastroenterology and Foundation for Research in Digestive Diseases, University Hospital Santiago de Compostela, c/Choupana s/n. Santiago de Compostela, Spain, Department of Pathology, University Hospital Santiago de Compostela, c/Choupana s/n. Santiago de Compostela, Spain, Department of General Surgery, University Hospital Santiago de Compostela, c/Choupana s/n. Santiago de Compostela, Spain
Published online on: November 23, 2010 https://doi.org/10.3892/ol.2010.206
Pages: 161-166

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic ductal adenocarcinoma results in high short-term mortality despite recent advances in diagnostics, surgery and chemotherapy. Modern chemotherapeutic agents directed to specific tumor receptors have higher therapeutic efficacy and lower adverse effects. However, few studies exist that evaluate the clinical impact in pancreatic cancer. The expression of tumor growth factor receptors, oncogenes and tumor suppressor oncogenes in surgical pancreatic cancer specimens as related to pathological characteristics, staging and prognosis was evaluated. Data were recorded for 50 patients who underwent a pancreatic cancer resection and were suitable for immunohistochemical evaluation (32 male, mean age 61 years, range 44-78) with regard to pTN, tumor size and location, histological differentiation grade, vascular and perineural invasion, adjuvant chemotherapy and survival time. Tumor specimens and normal pancreatic tissue were deparaffinized and the expression of vascular epidermal growth factor (VEGF) receptors (R)-1 and -2, epidermal growth factor receptor (EGFR), Her-2/neu, COX-2, p16, p21 and p53 was immunohistochemically evaluated using tissue microarrays. Associations between molecular marker expression and clinicopathological tumor characteristics were evaluated using the Chi-square test (SPSS) and the survival time was defined. The Kaplan-Meier method was utilized to analyze survival curves, verified by the log-rank test. No molecular markers evaluated were expressed in normal tissue. Tumor expression data included VEGF-R1 (74%), EGFR (52%), Her-2/neu (7.84%), COX-2 (21.5%), p16 (29.4%), p21 (21.7%) and p53 (50%). Tumors expressing VEGF-R1, EGFR and/or p53 were larger (p<0.02), frequently poorly differentiated (p<0.05) and more frequently associated with perineural and lymph node invasion (p<0.05). Marker expression did not correlate with pathological tumor characteristics. The median post-surgery survival was 15 months; 60 and 27% patients survived to 12 and 24 months, respectively, with a longer survival time in patients receiving adjuvant chemotherapy (n=20) (median 36 vs. 15 months, p<0.02). Growth factor receptors, oncogenes and tumor suppressor genes were frequently expressed in pancreatic cancer tissue. VEGF-R1, EGFR and p53 expression were associated with poor tissue differentiation and perineural and lymph node infiltration. Only VEGF-R1 expression was associated with a longer survival time and a more favorable response to adjuvant chemotherapy.

View Figures

View References

1	Mortalidad por cáncer en Espana. 2005, www.aecc.esurisimplewww.aecc.es.
2	Crist DW and Cameron JL: The current status of the Whipple operation for periampullary carcinoma. Adv Surg. 36:59–152. 1992.
3	Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L and Yeo CJ: p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res. 54:3025–3033. 1996.PubMed/NCBI
4	Garcia JF, Camacho FI, Morente M, Fraga M, Montalban C, Alvaro T, Bellas C, Castano A, Diez A, Flores T, Martin C, Martinez MA, Mazorra F, Menarguez J, Mestre Mj, Mollejo M, Saez AI, Sanchez L and Piris MA; Spanish Hodgkin’s Lymphoma Study Group. Hodgkin’s and Reed-Stenberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood. 101:681–689. 2003.
5	Googins M, Achutte M, Lu J, Moskaluk CA, Weinstein CL and Petersen GM: Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 56:5360–5364. 1996.PubMed/NCBI
6	Huang L, Goodrow TL, Zhang S, Klein-Szanto AJP, Chang H and Ruggeri BA: Deletion and mutation analyses of the p16/MTS1 tumour suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. Cancer Res. 56:1137–1141. 1996.
7	Moskaluk CA, Hruban RH and Kern SE: P16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res. 57:2140–2143. 1997.PubMed/NCBI
8	Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S and Zaurak M: Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 57:1731–1734. 1997.PubMed/NCBI
9	Kawesha A, Chaneh P, Andren-Sandberg A, Ograed D, Skar R and Dawiskiba S: K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16INK4A, p21WAF-1, cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer. 89:469–474. 2000. View Article : Google Scholar : PubMed/NCBI
10	Suzuki T and Takano Y: Comparative immunohistochemical studies of p53 and proliferating cell nuclear antigen expression and argyrophilic nucleoral organizer regions in pancreatic duct cell carcinomas. Jpn J Cancer Res. 84:1072–1077. 1993. View Article : Google Scholar
11	Zhang SY, Ruggeri B, Agarwal P, Sorling AF, Obara T and Ura H: Immunohistochemical analysis of p53 expression in human pancreatic carcinomas. Arch Pathol Lab Med. 118:150–154. 1994.PubMed/NCBI
12	Dergham ST, Dugan MC, Kucway R, Du W, Kamarauskiene DS and Vaitkevicius VK: Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma. Int J Pancreat. 21:127–143. 1997.PubMed/NCBI
13	Ruggeri BA, Huang L, Berger D, Chang H, Klein-Szanto AJ and Goodrow T: Molecular pathology of primary and metastatic ductal pancreatic lesions. Cancer. 79:700–716. 1997. View Article : Google Scholar : PubMed/NCBI
14	Gansauge F, Gansauge S, Schmidt E, Muller J and Beger HG: Prognostic significance of molecular alterations in human pancreatic carcinoma – an immunohistological study. Langenbecks Arch Surg. 383:152–155. 1998.
15	Yokoyama M, Yamanaka Y, Friess H, Buchler M and Murray K: P53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness. Anticancer Res. 14:2477–2483. 1997.PubMed/NCBI
16	Jeong J, Park YN, Park JS, Yoon DS, Chi HS and Kim BR: Clinical significance p16 protein expression loss and aberrant p53 protein expression in pancreatic cancer. Yonsei Med J. 46:519–525. 2005. View Article : Google Scholar : PubMed/NCBI
17	Dergham S, Dugan M, Joshi U, Chen Y, Du W, Smith D, Arlauskas P, Crissman J, Vaitkevicius V and Sarkar F: The clinical significance of p21 WAF1/CIP-1 and p53 expression in pancreatic adenocarcinoma. Cancer. 80:372–381. 1997. View Article : Google Scholar : PubMed/NCBI
18	Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML and Sinicrope FA: Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 59:4356–4362. 1999.PubMed/NCBI
19	Kokawa A, Kondo H, Gotoda T, Ono H, Saito D, Nakadaira S, Kosuge T and Yoshida S: Increased expression of cyclooxigenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer. 91:333–338. 2001. View Article : Google Scholar : PubMed/NCBI
20	Okami J, Yamamoto H, Fujiwara Y, Tsujie M, Kondo M, Noura S, Oshima S, Nagano H, Dono K, Umeshita K, Ishikawa O, Sakon M, Matsuura N, Nakamori S and Monden M: Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res. 5:2018–2024. 1999.PubMed/NCBI
21	Koshiba T, Hosotani R, Miyamoto Y, Wada M, Lee JU, Fujimoto K, Tsuji S, Nakajima S, Doi R and Imamura M: Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors. Int J Pancreatol. 26:69–76. 1999. View Article : Google Scholar
22	Williams TM, Weiner DB, Greene MI and Maguire HC: Expression of erbB-2 in human pancreatic adenocarcinoma. Pathobiology. 59:46–52. 1991. View Article : Google Scholar : PubMed/NCBI
23	Day DJ, Di Giuseppe JA and Yeo C: Immunohistochemical evaluation of Her-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplams. Hum Pathol. 27:119–124. 1996. View Article : Google Scholar
24	Hall PA, Hughes CM, Staddon SL, Richman PI, Gullick WJ and Lemoine NR: The c-erbB-2 proto-oncogene in human pancreatic cancer. J Pathol. 161:195–200. 1990. View Article : Google Scholar : PubMed/NCBI
25	Yamanaka Y, Friess H and Kobrin MS: Overexpression of Her2/neu oncogene in human pancreatic carcinoma. Human Pathol. 24:1127–1134. 1993. View Article : Google Scholar : PubMed/NCBI
26	Dugan MC, Dergham ST and Kucway R: Her-2/neu expression in pancreatic adenocarcinoma: relation to tumour differentiation and survival. Pancreas. 14:229–236. 1997. View Article : Google Scholar : PubMed/NCBI
27	Sirivatanauksorn V, Sirivatanauksorn Y and Lemoine NR: Molecular pattern of ductal pancreatic cancer. Langenbecks Arch Surg. 383:105–115. 1998. View Article : Google Scholar : PubMed/NCBI
28	Lemoine NR, Hughes CM and Barton CM: The epidermal growth factor receptor in human pancreatic cancer. J Pathol. 166:7–12. 1992. View Article : Google Scholar : PubMed/NCBI
29	Kioppel G, Maillet B and Schewere K: Immunocytochemical detection of epidermal growth factor receptor (EGFr) and transferrin receptor (TR) on normal, inflamed and neoplastic pancreatic tissue. Pancreas. 4:6231989.
30	Uegaki K, Nio Y and Inoue Y: Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. Anticancer Res. 17:3841–3848. 1997.PubMed/NCBI
31	Sterm DF and Kamps MP: EGF-stimulated tyrosine phos-phorylation of p185neu a potential model of receptor interactions. EMBO J. 7:995–1001. 1988.PubMed/NCBI
32	Kokai Y, Myers JN and Wada T: Synergistic interaction of p185neu and EGF receptor leads to transformation of rodent fibroblasts. Cell. 58:287–292. 1989. View Article : Google Scholar : PubMed/NCBI
33	Millauer B, Wizigmann-Voss S and Schunürch H: High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell. 72:835–846. 1993. View Article : Google Scholar : PubMed/NCBI
34	Ferrara N and Henzel WJ: Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 161:851–858. 1989. View Article : Google Scholar
35	Gospodarowicz D and Lau K: Pituitary follicular cells secrete both vascular endothelial growth factor and follistatin. Biochem Biophys Res Commun. 165:292–298. 1989. View Article : Google Scholar : PubMed/NCBI
36	De Vries C, Escobedo JA and Ueno H: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 255:989–991. 1992.
37	Terman BI, Dougher-Vermazen M and Carrion ME: Identification of KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun. 187:1579–1586. 1992. View Article : Google Scholar : PubMed/NCBI
38	Chen H, Chedotal A and He Z: Neuropilin-2 a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III. Neuron. 19:547–559. 1997. View Article : Google Scholar : PubMed/NCBI
39	Brown JM and Giaccia AJ: The unique physiology of solid tumors. Opportunities (and problems) for cancer therapy. Cancer Res. 58:1408–1416. 1998.PubMed/NCBI
40	Itakura J, Ishiwata T and Friess H: Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res. 3:1309–1316. 1997.PubMed/NCBI
41	Seo Y, Baba H, Fukuda T, Takashima M and Sugimachi K: High expression of vascular endothelial growth factor is associated with liver metastasis and poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer. 88:2239–2245. 2000. View Article : Google Scholar : PubMed/NCBI
42	Ellis LM, Takahashi Y, Fenoglio CJ, Cleary KR, Bucana CD and Evans DB: Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. Eur J Cancer. 34:337–340. 1998. View Article : Google Scholar : PubMed/NCBI
43	Fujimoto K, Hosotani R and Wada M: Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis. Eur J Cancer. 34:1439–1447. 1998. View Article : Google Scholar
44	Buchler P, Peber HA, Buchler MW, Friess H and Hines OJ: VEGF-RII influences the prognosis of pancreatic cancer. Ann Surg. 236:738–749. 2002. View Article : Google Scholar : PubMed/NCBI
45	Chung G, Yoon H, Zerkowsi M, Ghosh S, Thomas L, Harigopal M, Charette L, Salem R, Camp R, Rimm D and Burtness B: Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in pancreatic cancer tissue microarray. Cancer. 106:1677–1684. 2006. View Article : Google Scholar : PubMed/NCBI